By contrast, in patients with critical disease, the beneficial effect of anti-IL-6/IL-6R/JAK antibodies on mortality became indistinct, and resulted in an evident trend of increased secondary infection rates. This evidence concerns the gene IL6R and glycogen storage disease VI.